drugset / Trial / NCT03526848
3BNC117 and 10-1074 in ART-treated Individuals
Phase 1
Completed
26 enrolled
Rockefeller University
Montefiore Medical Center · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabRagon Institute of MGH, MIT and Harvard · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The proposed study is a phase 1, open label, randomized study to evaluate the safety and antiretroviral activity of seven infusions of 3BNC117 and 10-1074, administered intravenously at 30 mg/kg dose level, in human immunodeficiency virus (HIV)-infected individuals on combination antiretroviral therapy (ART) and during an analytical interruption of ART.
Timeline
- Start
- 2018-06-05
- Primary completion
- 2021-09-30
- Completion
- 2022-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LAFUVITUG | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | Zinlirvimab | Monoclonal antibody | 30 mg/kg | Intravenous |